<DOC>
	<DOCNO>NCT01242449</DOCNO>
	<brief_summary>This phase II study investigate oral vinorelbine 90 mg/m2 day 1 + 8 3 week interval combination trastuzumab 1st 2nd line treatment woman metastatic HER2 positive breast cancer . Oral vinorelbine show overall response rate i.v . vinorelbine metastatic breast cancer , capsule generally well tolerate .</brief_summary>
	<brief_title>Oral Vinorelbine Combination With Trastuzumab Metastatic Breast Cancer</brief_title>
	<detailed_description />
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Trastuzumab</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<criteria>Woman ≥ 18 year age . PS 02 . Expected lifetime 12 week . Histologically verify breast cancer ( adenocarcinoma ) Primary tumor metastasis HER2 positive IHC3+ FISH+ ( ratio ≥ 2.2 ) . Documented metastatic breast cancer min . one lesion measureable accord RECIST 1.1 criterion . All solitary lesion must verify cytologically/histologically represent evidence malignancy . The patient may receive ( neo ) adjuvant chemotherapy ( taxanes , anthracyclines trastuzumab ) 1st line chemotherapy combination trastuzumab metastatic disease . The patient may receive previous adjuvant antihormonal treatment metastatic breast cancer . The patient may receive radiation therapy , however , lesion use response evaluation . Normal heart function , LVEF ≥ 50 % measure MUGA/EKKO . Normal bone marrow function : Hemoglobin ≥ 6 mmol/l , ANC ≥ 1.5x10^9/l . Thrombocytes ≥ 100x10^9/l . Normal liver function : Bilirubin ≤ 1.5 x upper normal level , ALAT ≤ 2.5 x upper normal level , BASP ≤ 2.5 x upper normal level ( ≤ 5 presence bone metastasis ) . Normal renal function : Creatinine ≤ upper normal level . In case raise creatinine measured/calculated GFR must ≥ 50 ml/min . Fertile woman must present negative pregnancy test use contraceptives 3 month treatment . An IUD without hormone consider safe contraceptive . Written orally inform consent prior study related procedure . Local recurrence counterlateral breast cancer without dissemination . Pregnant breastfeed woman . Clinical symptom CNS metastasis , incl . meningeal carcinomatosis . Malabsorption syndrome disease affect gastrointestinal function . Resection ventriculus small intestine , affect absorption oral vinorelbine . Dysphagia condition prevent patient swallow tablet . Mental social condition prevent treatment followup . Serious concurrent medical condition , : AMI within 12 month unstable angina . Heart incompensation NYHA III IV uncontrolled hypertension ( systolic &gt; 150 mm/hg and/or diastolic &gt; 100 mm/hg ) . Serious arrythmia require medication , excl . atrial fibrillation paroxystic supraventricular tachycardia . Active infection , uncontrolled diabetes hypercalcemia . Other concurrent experimental treatment . Concurrent antihormonal treatment metastatic breast cancer . Known neuropathia ≥ grade 2 . Other previous malignant disease within past 5 year excl . nonmelanoma skin cancer carcinoma situ cervicis uterus . Previous treatment vinca alkaloid . Previous serious allergic unexpected reaction trastuzumab treatment .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2015</verification_date>
	<keyword>Breast cancer</keyword>
	<keyword>Metastatic</keyword>
	<keyword>HER2 positive</keyword>
	<keyword>vinorelbine</keyword>
</DOC>